NIHR HIC CV+: Using the strengths of the NIHR Health Informatics Collaborative (HIC) to analyse the wider implications of the Covid-19 pandemic on cardiovascular health
- Funded by British Heart Foundation
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19Start & end year
N/AFunder
British Heart FoundationPrincipal Investigator
Unspecified Jamil MayetResearch Location
United KingdomLead Research Institution
N/AResearch Priority Alignment
N/A
Research Category
Clinical characterisation and managementResearch Subcategory
Prognostic factors for disease severitySpecial Interest Tags
N/AStudy Type
ClinicalClinical Trial Details
Not applicableBroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
This project builds on an established dataset from over 250,000 patients gathered from six large NHS Trusts: Oxford University College Hospitals, King's College Hospital, Guy's & St Thomas' Hospitals, University College London Hospitals and Imperial College Healthcare. The data are being used to assess the effects of a series of clinical measures and treatment decisions on the severity of cardiovascular outcomes. Led by Professor Jamil Mayet, Professor of Cardiology at Imperial College and leader of the HIC Cardiovascular Theme, the team will add Covid-19-related data and substantially increase the number of hospital trusts contributing routine clinical information. With collaborators from HDR UK, NHSX, NHS Digital and NICOR co-ordinated through the BHF Data Science Centre, the project has three initial aims: 1. Estimating the prognostic value of specific cardiac biomarkers to predict severity of acute cardiac complications due to Covid-19 infection. 2. Understanding the pattern of all cardiovascular admissions to hospital during the Covid-19 pandemic, particularly in the light of the observed decline in the number of non-Covid related cardiovascular admissions. 3. Assessing the effects of commonly prescribed medications on predictive biomarkers and outcome